Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Multi-site disease analytics with applications to estimating COVID-19 undetected cases in Canada

View ORCID ProfileMatthew R. P. Parker, Jiguo Cao, Laura L. E. Cowen, Lloyd T. Elliott, Junling Ma
doi: https://doi.org/10.1101/2022.07.11.22277508
Matthew R. P. Parker
1Department of Statistics and Actuarial Science, Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew R. P. Parker
  • For correspondence: matthew_parker_2{at}sfu.ca lcowen{at}uvic.ca
Jiguo Cao
1Department of Statistics and Actuarial Science, Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura L. E. Cowen
2Department of Mathematics and Statistics, University of Victoria, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matthew_parker_2{at}sfu.ca lcowen{at}uvic.ca
Lloyd T. Elliott
1Department of Statistics and Actuarial Science, Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junling Ma
2Department of Mathematics and Statistics, University of Victoria, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Even with daily case counts, the true scope of the COVID-19 pandemic in Canada is unknown due to undetected cases. We estimate the pandemic scope through a new multi-site model using publicly available disease count data including detected cases, recoveries among detected cases, and total deaths. These counts are used to estimate the case detection probability, the infection fatality rate through time, as well as the probability of recovery, and several important population parameters including the rate of spread, and importation of external cases. We also estimate the total number of active COVID-19 cases per region of Canada for each reporting interval. We applied this multi-site model Canada-wide to all provinces and territories, providing an estimate of the total COVID-19 burden for the 90 weeks from 23 Apr 2020 to 6 Jan 2022. We also applied this model to the five Health Authority regions of British Columbia, Canada, describing the pandemic in B.C. over the 31 weeks from 2 Apr 2020 to 30 Oct 2020.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

LC was supported by a Michael Smith Foundation for Health Research and Victoria Hospitals Foundation Grant #COV-2020-1061 and a Canadian Statistical Sciences Institute Rapid Response Program: COVID-19.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data was downloaded from publicly available government sources: BCCDC (Weekly Surveillance Reports), PHAC (COVID-19 epidemiology update), and Yukon Health (COVID-19 Dashboard Data). Data used has been archived here: https://github.com/mrparker909/COVID-MultiSiteModel2022.git

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† Authors listed in alphabetical order.

Data Availability

All data are available online at: https://github.com/mrparker909/COVID-MultiSiteModel2022.git

https://github.com/mrparker909/COVID-MultiSiteModel2022.git

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted July 12, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Multi-site disease analytics with applications to estimating COVID-19 undetected cases in Canada
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multi-site disease analytics with applications to estimating COVID-19 undetected cases in Canada
Matthew R. P. Parker, Jiguo Cao, Laura L. E. Cowen, Lloyd T. Elliott, Junling Ma
medRxiv 2022.07.11.22277508; doi: https://doi.org/10.1101/2022.07.11.22277508
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Multi-site disease analytics with applications to estimating COVID-19 undetected cases in Canada
Matthew R. P. Parker, Jiguo Cao, Laura L. E. Cowen, Lloyd T. Elliott, Junling Ma
medRxiv 2022.07.11.22277508; doi: https://doi.org/10.1101/2022.07.11.22277508

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)